This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 34 open trials.
In 127 locations
What is a Clinical Trial?
There are currently 34 open trials
- Effects of an exercise programme on smouldering myeloma and MGUS
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- GMI-1271 with standard of care for the treatment of multiple myeloma
- Post authorisation study of Pomalidomide (Imnovid)
- Daratumumab in combination with standard multiple myeloma treatment
- GSK2857916 in patients who have failed prior treatment with an anti-CD38 antibody (DREAMM 2)
- MGUS research study
- AZD4573 in relapsed or refractory myeloma
- Daratumumab vs. monitoring in high risk smouldering myeloma
- Selinexor for relapsed and refractory myeloma (BOSTON)
- RO6870810 monotherapy and combination for relapsed and refractory myeloma patients
- Subcutaneous vs. intravenous daratumumab in relapsed and/or refractory myeloma
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Targeted radiotherapy for myeloma
- Pre-transplant exercise for myeloma patients (PREeMPT)
- Observational study of presentation, treatment and outcomes in myeloma patients (INSIGHT-MM)
- Observational evaluation of myeloma patients (PREAMBLE)
- Image guided theranostics in myeloma (iTIMM)
- Ixazomib maintenance treatment for newly diagnosed myeloma patients
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- MUK eleven (Reolysin trial)
- Myeloma XII (ACCoRd)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients
- MUK seven
- MUK eight
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK525762 trial
Trial Title:
Effects of an exercise programme on smouldering myeloma and MGUS
Treatments:
Exercise programme
Myeloma stage:
Smouldering, MGUS
Trial phase:
Summary:
The aim of this study is to assess the feasibility and safety of a progressive, walking-based exercise programme for smouldering myeloma and MGUS, and to assess the impact of exercise on disease activity.
Locations:
Royal United Hospital, Bath
Who can enter the study?:
Patients with smouldering myeloma or monoclonal gammopathy of undetermined significance (MGUS).
What's involved?:
Patients are randomised to receive either a progressive exercise programme or usual care for 16 weeks.
The exercise programme consists of two supervised group classes per week and one session at home. The exercise programme includes cardio, strengthening and balance exercises, and stretching.
Disease activity, physical fitness and quality of life are measured throughout the study and again at 17 weeks.
The usual care control group are offered the exercise programme at the end of their participation in the study.
Clinical Information
(for Medical Professionals):
Find out more: